Research & Citations
Peer-reviewed findings that support the site thesis. Abstracts abridged for education. Read the original before you quote a number in a fight. Jump: adulteration · liver · ED visits · metals · interactions · FDA comfrey/ephedra · GAIT · WHO.
1. Widespread herbal-product adulteration (DNA methods)
Ichim MC. The DNA-Based Authentication of Commercial Herbal Products Reveals Their Globally Widespread Adulteration. Front Pharmacol. 2019;10:1227. doi:10.3389/fphar.2019.01227
On-site line: Across 5,957 commercial herbal products from 37 countries, 27% failed a DNA identity check against the labeled species.
Abstract / finding: This review pooled DNA-authentication studies of finished herbal products sold on the open market. Adulteration included undeclared contaminants, substitutes, fillers, or absence of the named species. Some of that is accident. Some of it is economic fraud. Follow-on work using chemical methods reported a similar overall rate. That is a better talking point than any single store-shelf sample.
2. DNA barcoding as a diagnostic tool
Thanakiatkrai P, Kitpipit T. A Review on Application of DNA Barcoding Technology for Rapid Molecular Diagnostics of Adulterants in Herbal Medicine. Drug Saf. 2022;45(3):193–213. doi:10.1007/s40264-021-01133-4
On-site line: Two decades of barcode data exist because identity fraud and substitution in herbal medicine are common enough to need a lab test.
Abstract / finding: Review of ITS, rbcL, matK, and trnH-psbA barcodes and the public databases used to match unknown material. You are not asking readers to trust a blogger. You are pointing at a field that exists because the supply chain fails identity tests.
3. Combined DNA + chemistry on weight-loss and cardio products
Hoban CL, et al. Toxicological screening and DNA sequencing detects contamination and adulteration in regulated herbal medicines and supplements for diet, weight loss and cardiovascular health. J Pharm Biomed Anal. 2019;176:112834.
On-site line: Nearly half of tested products had a DNA problem, a chemistry problem, or both — including undeclared pharmaceuticals and stimulants.
Abstract / finding: Nearly 50% of products had contamination issues by DNA, chemistry, or both. Two samples were pharmaceutical adulteration (including paracetamol plus chlorpheniramine). Undeclared stimulants included caffeine, synephrine, and ephedrine. DNA also flagged allergen and animal-material surprises. The bottle is not a controlled object.
4. Liver injury — U.S. DILIN
Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology. 2014;60(4):1399–1408. doi:10.1002/hep.27317. PMID:25043597
On-site line: Herbals and dietary supplements went from 7% to 20% of DILIN liver-injury cases. Non-bodybuilding HDS injury ended in death or transplant more often than prescription-drug injury (13% vs 3%).
Abstract (abridged): DILIN enrolls hepatotoxicity from conventional drugs and from herbals/dietary supplements. HDS liver injury rose from 7% to 20% during the study period. Bodybuilding products caused long jaundice in young men without death or transplant in that subset. Other HDS cases were hepatocellular, mostly in middle-aged women, and had worse outcomes than medication cases.
5. Emergency department burden
Geller AI, Shehab N, Weidle NJ, et al. Emergency Department Visits for Adverse Events Related to Dietary Supplements. N Engl J Med. 2015;373:1531–1540. doi:10.1056/NEJMsa1504267. PMID:26465986
On-site line: About 23,000 U.S. emergency visits a year, and about 2,150 hospitalizations, were attributed to dietary-supplement adverse events.
Abstract (abridged): Nationally representative ED surveillance, 3,667 cases. Estimated 23,005 ED visits per year (95% CI 18,611–27,398) and 2,154 hospitalizations. Visits clustered in adults 20–34 and in unsupervised children. Excluding child ingestions, 65.9% of single-supplement visits involved herbal or complementary products; weight-loss and energy products drove palpitations, chest pain, and tachycardia.
6. Heavy metals in Ayurvedic products
Saper RB, et al. Heavy Metal Content of Ayurvedic Herbal Medicine Products. JAMA. 2004;292(23):2868–2873.
Saper RB, et al. Lead, Mercury, and Arsenic in US- and Indian-Manufactured Ayurvedic Medicines Sold via the Internet. JAMA. 2008;300(8):915–923.
On-site line: One in five Ayurvedic products tested — including products sold as U.S.-made — contained lead, mercury, or arsenic at doses that would exceed accepted daily intake.
Findings: 2004: 14 of 70 South Asian Ayurvedic products sold near Boston contained lead, mercury, and/or arsenic; taken as directed, each of those 14 exceeded published intake standards. 2008: 20.7% of 193 internet-purchased Ayurvedic medicines contained detectable lead, mercury, or arsenic. Rasa shastra products were worse. A GMP claim on the website did not predict a clean bottle.
7. Herb–drug interactions clinicians already act on
Asher GN, Corbett AH, Hawke RL. Common Herbal Dietary Supplement–Drug Interactions. Am Fam Physician. 2017;96(2):101–107.
Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001;286(2):208–216.
On-site line: St. John's wort and goldenseal are "avoid with other drugs" problems. Garlic, ginkgo, and ginseng are treated as bleeding and anesthesia problems. Default pre-op instruction is to stop them.
Finding: St. John's wort induces CYP3A4 and P-glycoprotein — cyclosporine, tacrolimus, warfarin, protease inhibitors, irinotecan, oral contraceptives. Perioperative review flags echinacea, ephedra, garlic, ginkgo, ginseng, kava, St. John's wort, and valerian for bleeding, heart rate, sedation, or drug-level changes. Half or more of surgical patients never mention the herb.
8. How the U.S. actually regulates the bottle
Dietary Supplement Health and Education Act of 1994; FDA, "FDA 101: Dietary Supplements."
On-site line: FDA does not approve dietary supplements for safety or effectiveness before they are sold. The company is on the hook. FDA mostly acts after the product is already on the shelf.
DSHEA put most oral herbs in a middle category between food and drug. Structure/function claims are allowed with the familiar disclaimer. Disease claims turn the product into an unapproved drug. That statutory split is why a plant with drug-level activity can still ship without the program described on the withdrawn-drugs page.
9. What a serious botanical would look like
van Breemen RB. Development of Safe and Effective Botanical Dietary Supplements. J Med Chem. 2015;58(21):8360–8372. doi:10.1021/acs.jmedchem.5b00417
On-site line: A serious botanical would be standardized to the active compound, checked for drug interactions, and tested in people. That is not how most retail herbs are built.
Identify the active constituents, standardize chemically and biologically, run preclinical toxicity and interaction work, then do clinical safety and efficacy. FDA GMP for supplements was a start. Efficacy is still not required.
10. FDA: oral comfrey / pyrrolizidine alkaloids
U.S. Food and Drug Administration. FDA Advises Dietary Supplement Manufacturers to Remove Comfrey Products From the Market. Letter, July 6, 2001.
On-site line: FDA told industry to pull oral comfrey because pyrrolizidine alkaloids are hepatotoxins, have been tied to hepatic veno-occlusive disease, and have no established safe oral exposure.
Finding: Common, prickly, and Russian comfrey contain PAs. Animal data and human outbreaks of hepatic VOD support the toxicity. FDA stated it was prepared to use its authority to remove products that appear to violate the Act. FTC separately required liver-damage warnings on remaining topical claims.
FDA letter (archive) · FTC comfrey case
11. FDA: ephedra / ephedrine-alkaloid ban
U.S. Food and Drug Administration. Final rule prohibiting dietary supplements containing ephedrine alkaloids. February 6, 2004; effective April 12, 2004. 69 Fed. Reg. 6788.
On-site line: FDA banned ephedra supplements because they present an unreasonable risk of illness or injury, including heart attack and stroke.
Finding: Ephedra (ma huang) contains ephedrine. When the same chemical is synthesized it is regulated as a drug. Marketed as a supplement for weight loss and "energy," it produced a large adverse-event file. The ban is the rare case of FDA using the DSHEA "unreasonable risk" clause to take a botanical off the shelf after the fact — not before.
12. GAIT — glucosamine and chondroitin for knee pain
Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795–808. doi:10.1056/NEJMoa052771. PMID:16495392
On-site line: In 1,583 patients, glucosamine and chondroitin alone or together did not beat placebo for a 20% pain reduction in the overall knee-OA group. Celecoxib did.
Abstract (abridged): Multicenter, double-blind, placebo- and celecoxib-controlled trial. Overall response vs placebo: glucosamine +3.9 points (P=0.30), chondroitin +5.3 (P=0.17), combination +6.5 (P=0.09), celecoxib +10.0 (P=0.008). An exploratory subgroup with moderate-to-severe baseline pain looked better on the combination. Adverse events were mild and even across arms.
13. WHO: quality and pharmacovigilance for herbal medicines
World Health Organization. Quality control methods for herbal materials. Geneva: WHO; 2011.
World Health Organization. WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems. Geneva: WHO; 2004.
On-site line: WHO treats poor identity, contamination, and missing adverse-event systems as primary reasons herbal products hurt people — not as a side issue.
Finding: The quality manual standardizes identity, purity, pesticide residues, toxic metals, microbes, and aflatoxins. The pharmacovigilance guideline tells national centers to collect herbal adverse reactions, look for interactions, and treat misidentification and adulteration as safety problems. That is the opposite of "natural means unregulated."
WHO quality methods · WHO herbal pharmacovigilance
14. Iron-containing products and children
Unintentional iron ingestion in children under six remains a classic poison-center problem. Adult and prenatal iron tablets look like candy. Unit-dose packaging rules in the late 1990s followed deaths in that age group. The site's "natural is not automatically safe" iron example is about dose and form, not about demonizing a mineral the body uses.
15. FDA 101 and the DSHEA split
U.S. Food and Drug Administration. FDA 101: Dietary Supplements. Consumer update.
FDA does not approve dietary supplements for safety or effectiveness before sale. Companies are responsible for safety. Structure/function claims require the DSHEA disclaimer. Disease claims turn the product into an unapproved drug. That is the statutory reason a plant with drug-level activity can still ship without the program on the withdrawn-drugs page.
16. Pesticide residues in herbal materials
Luo L, et al. Detection and risk assessments of multi-pesticides in 1771 cultivated herbal medicines by LC/MS-MS and GC/MS-MS. Chemosphere. 2021;262:127477. doi:10.1016/j.chemosphere.2020.127477. PMID:32799136
On-site line: Science proves "pesticides in herbs" sometimes exists. These are farmed plants. They get sprayed.
Abstract (abridged): Pesticides were present in 88% of 1,771 cultivated herbal-medicine samples. More than half (59%) exceeded the European Pharmacopoeia limit. Forty-three percent contained banned, extremely toxic pesticides; eight detections were more than 500 times a default maximum residue limit. DDTs, carbofuran, and mevinphos ranked among the highest-risk residues (carcinogenic, genotoxic, reproductive/developmental, nephrotoxic, hepatotoxic).
Wang Y, et al. Levels and Health Risk of Pesticide Residues in Chinese Herbal Medicines. Front Pharmacol. 2022;12:818268. doi:10.3389/fphar.2021.818268. PMID:35177984
Finding: 168 pesticides screened in 1,017 samples of 10 Chinese herbal medicines. Residues in 89.2% of samples. Aboveground medicinal parts were dirtier than underground parts. Banned pesticides still showed up in actual planting practice.
World Health Organization. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. Geneva: WHO; 2007.
WHO lists pesticide residues next to toxic metals, microbes, and aflatoxins as contaminants that have to be measured. "Natural plant" is not a residue-free claim.
17. Ginkgo does not slow cognitive decline — GEM trial
Snitz BE, et al. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA. 2009;302(24):2663–2670. doi:10.1001/jama.2009.1913. PMID:20040554
On-site line: The memory-herb claim is a retail claim. In 3,069 adults aged 72–96 followed a median 6.1 years, 120 mg twice daily did not slow decline in any cognitive domain versus placebo.
18. St. John's wort in major depression
Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA. 2002;287(14):1807–1814. PMID:11939866
On-site line: In moderately severe major depression, St. John's wort was not better than placebo on the primary Hamilton scores. It still induces CYP3A4 — so you can get the interaction without the benefit.
19. Saw palmetto and BPH
Tacklind J, MacDonald R, Rutks I, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2009;(2):CD001423. PMID:19370565
On-site line: Saw palmetto was not more effective than placebo for urinary symptoms consistent with BPH.
20. Black cohosh and hot flashes
Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med. 2006;145(12):869–879. PMID:17179056
On-site line: Black cohosh alone or in a multibotanical mix did not beat placebo for hot flashes. Hormone therapy did.
21. Echinacea and the common cold
Turner RB, Bauer R, Woelkart K, Hulsey TC, Gangemi JD. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med. 2005;353(4):341–348. PMID:16049208
On-site line: Controlled rhinovirus challenge did not show a prevention or treatment win for the echinacea preparations tested.
22. Milk thistle / silymarin in chronic hepatitis C
Fried MW, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA. 2012;308(3):274–282. PMID:22782416
On-site line: Higher-than-usual oral silymarin doses did not improve liver enzymes or viral outcomes versus placebo in interferon-unresponsive chronic hepatitis C.
23. Class I recalls: hidden drugs in "supplements"
Harel Z, Harel S, Wald R, Mamdani M, Bell CM. The frequency and characteristics of dietary supplement recalls in the United States. JAMA Intern Med. 2013;173(10):926–930. doi:10.1001/jamainternmed.2013.379. PMID:23588257
On-site line: How you tell a company you cannot trust: more than half of U.S. Class I drug recalls from 2004–2012 were dietary supplements, every one of them for undeclared drug ingredients. Sexual-enhancement, bodybuilding, and weight-loss products dominated.
24. What a manufacturer is actually required to do
U.S. Food and Drug Administration. Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. 21 CFR Part 111.
U.S. Food and Drug Administration. FDA 101: Dietary Supplements.
On-site line: GMP is the floor, not a halo. Identity, purity, strength, and composition are the company's job. Premarket proof of effectiveness is still not required. A firm that will not discuss testing, lot numbers, or warnings is asking you to skip the only safety system the statute left standing.